News & Updates

Colorectal cancer screening can wait until age 50
Colorectal cancer screening can wait until age 50
20 Sep 2023 byElvira Manzano

Colorectal cancer screening should wait until age 50 for average-risk, asymptomatic adults, says the American College of Physicians (ACP) in its updated guidance. However, this stands in contrast to screening recommendations by the American Cancer Society (ACS) and the US Preventive Services Task Force (USPSTF) to start at age 45.

Colorectal cancer screening can wait until age 50
20 Sep 2023
Extended anticoagulation benefits cancer patients with distal DVT
Extended anticoagulation benefits cancer patients with distal DVT
20 Sep 2023 byAudrey Abella

In cancer patients with isolated distal deep vein thrombosis (IDDVT), a 12-month anticoagulation regimen with the oral factor Xa inhibitor edoxaban fared better than a 3-month regimen, findings from the ONCO DVT study have shown.

Extended anticoagulation benefits cancer patients with distal DVT
20 Sep 2023
Liver transplant confers better long-term survival in select CRC patients
Liver transplant confers better long-term survival in select CRC patients
19 Sep 2023

In the treatment of patients with nonresectable colorectal cancer (CRC) with liver metastases, liver transplantation may improve long-term survival outcomes especially when performed for those with favourable prognostic scoring, according to a study.

Liver transplant confers better long-term survival in select CRC patients
19 Sep 2023
CML-specific app scores low on uptake, awareness among patients
CML-specific app scores low on uptake, awareness among patients
19 Sep 2023 byStephen Padilla

Patients with chronic myeloid leukaemia (CML) appear to be unaware or have low acceptance of a healthcare app specifically develop to manage their disease, reports a study.

CML-specific app scores low on uptake, awareness among patients
19 Sep 2023
Does UV-B phototherapy increase the risk of skin cancer in AD patients?
Does UV-B phototherapy increase the risk of skin cancer in AD patients?
18 Sep 2023
Durvalumab plus radiotherapy shows promise in unresectable NSCLC
Durvalumab plus radiotherapy shows promise in unresectable NSCLC
17 Sep 2023

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

Durvalumab plus radiotherapy shows promise in unresectable NSCLC
17 Sep 2023